TVTX — Travere Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$66.44
+$0.73 (+1.12%)
Travere Therapeutics Inc (TVTX) is a biotechnology company listed on NASDAQ. It is led by Eric M. Dube Ph.D., based in 3611 Valley Centre Drive, San Diego, CA, United States, 92130, with about 385 employees. Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest reported TVTX revenue for 2025-09-30 was $164.9M. Net income was $25.7M. Revenue was up 44.0% from 2025-06-30 to 2025-09-30. TVTX currently screens at market cap $1.33B.
Use this TVTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TVTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TVTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Travere Therapeutics Inc even when a live quote feed is slow.
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
TVTX Key Statistics
Market Cap
$1.33B
Volume
808,139
Previous Close
$67.52
Day Range
$65.37 – $67.45
EPS
-$4.08
Revenue
$233.18M
Net Income
-$321.55M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+417.5%
Profit Margin
-137.9%
Employees
385
TVTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $233.18M | $45.06M | $29.34M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$321.55M | -$90.17M | -$65.82M |
| EPS (Diluted) | -$4.08 | -$1.18 | -$1.03 |
Total Assets
$594.13M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$58.53M
Operating Cash Flow
-$237.47M
Free Cash Flow
$0.00
Travere Therapeutics Inc Company Information
- President, CEO & Director
- Eric M. Dube Ph.D.
- Headquarters
- 3611 Valley Centre Drive, San Diego, CA, United States, 92130
- Website
- www.travere.com
- Phone
- 888 969 7879
- IPO / Founded
- 2012-11-08
- Sector
- Healthcare
- Industry
- Biotechnology